We found multiple hotspots and driver mutations in the BRAF/MEK/PI3K pathway (Figure 6A), which are crucial for tumor progression, growth, survival, and therapy resistance in CRC and other tumors like melanoma and breast cancer, due to abnormal kinase activation and pathways. This evidence concerns the gene MAP2K7 and breast carcinoma.